Adult T-cell leukemia/lymphoma

Oliveira, Pedro Dantas; Farre, Lourdes; Bittencourt, Achiléa Lisboa

doi:10.1590/1806-9282.62.07.691

Cited by 20 publications

(22 citation statements)

References 69 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ATLL is an aggressive T‐cell proliferation which is developed in the infected individuals after a lengthy latency period. The leukemic cells are monoclonal and mostly displayed the immunophenotype of CD2+/CD3+/CD4+/CD5+/CD7‐/CD8‐/CD20‐/CD79a‐/CD25+ . HAM/TSP mainly targets the neurologic cells and causes the increase in the expression level of some cytokines, adhesion molecules, Fas/Fas ligand, and molecules impressing T cell migration in the lesions.…”

Section: Introductionmentioning

confidence: 99%

Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study

Mozhgani¹,

Zarei-Ghobadi²,

Teymoori‐Rad³

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

The main mechanisms of interaction between Human T-lymphotropic virus type 1 (HTLV-1) and its hosts in the manifestation of the related disease including HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and Adult T-cell leukemia/lymphoma (ATLL) are yet to be determined. It is pivotal to find out the changes in the genes expression toward an asymptomatic or symptomatic states. To this end, the systems virology analysis was performed. Firstly, the differentially expressed genes (DEGs) were taken pairwise among the four sample sets of Normal, Asymptomatic Carriers (ACs), ATLL, and HAM/TSP. Afterwards, the protein-protein interaction networks were reconstructed utilizing the hub genes. In conclusion, the pathways of cells proliferation and transformation were identified in the ACs state. In addition to immune pathways in ATLL, the inflammation and cancer pathways were discened in both diseases of ATLL and HAM/TSP. The outcomes can specify the genes involved in the pathogenesis and help to design the drugs in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study

Mozhgani¹,

Zarei-Ghobadi²,

Teymoori‐Rad³

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…This action could contribute to control HTLV replication. Although initial observations suggested that the synthesis of 1,25(OH) 2 D and PTHrP by HTLV-infected lymphocytes in patients with ATL was associated with hypercalcemia, the main cause of death in patients with ATL, subsequent studies failed to show increased levels of 1,25(OH) 2 D and PTHrP [38,41]. A prospective study of subjects admitted to a hematology unit evaluated the incidence of hypercalcemia and the association with humoral mechanisms involving PTHrP, parathyroid hormone (PTH) and 1,25(OH) 2 D. Hypercalcemia was detected in few subjects and was caused by primary hyperparathyroidism.…”

Section: Discussionmentioning

confidence: 99%

“…The role of the immune response in HTLV pathogenesis is not fully understood, but the efficacy of the individual immune response defines the control or limitation of viral persistence and, ultimately, the outcome of HTLVassociated diseases [34 -37]. HTLV can immortalize human lymphocytes, specially TCD4 + lymphocytes in ATL [38].…”

Section: Introductionmentioning

confidence: 99%

Vitamin D and HTLV Infection: A Systematic Review

Netto¹,

Gomes‐Neto²,

Brites³

2019

TOIDJ

View full text Add to dashboard Cite

Background:Vitamin D has been associated with the pathogenesis of infectious diseases.Objective:To perform a systematic review on the association of vitamin D and outcomes of HTLV (Human T-cell lymphotropic virus) infection.Methods:We searched PubMed, LILACs, Scielo, Embase and Cochrane Library for studies addressing vitamin D and HTLV infection. We included studies published in English since 1980. Studies associated with HIV, bone metabolism and not related to HTLV- associated myelopathy/ tropical spastic paraparesis (HAM/TSP) or adult T cell leukemia/lymphoma (ATL) were excluded.Results:Twenty-three studies were selected and sixteen studies were included in the review (eight experimental studies, three case reports, three cases series, one cross-sectional study and one review). Fourteen studies were focused on ATL, and two on HAM/TSP. The available data show thatin vitroexposure to 1,25(OH)2D inhibits proliferation of HTLV-infected lymphocytes in patients with ATL or HAM/TSP. It has been observed that hypercalcemia, the main cause of death in patients with ATL, is not associated with serum levels of 1,25(OH)2D or parathyroid hormone-related protein, but leukemia inhibitory factor/D factor seems to be an important factor for hypercalcemia pathogenesis. It was also demonstrated an association between the VDRApaIgene polymorphism and a decreased risk of HAM/TSP in HTLV positive individuals.Conclusion:Despite the small number and heterogeneity of the studies, this systematic review suggests that vitamin D play a role in the pathogenesis of HTLV-associated diseases.

show abstract

“…CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen cen be used with 25% CRR. Hyper-CVAD (cyclophospha mide, vincristine, doxorubicin, and dexamethasone-meth otrexate, cytarabine) is acceptable as an alternative regimen [21]. Combination of Zidovudine and IFN-α shown to be effective in the leukemic subtypes in a meta-analysis.…”

Section: Adult T Cell Leukemia/lymphomamentioning

confidence: 99%

Primary Cutaneous Lymphomas and Interferon Treatment

MC¹

2017

J Hematol Clin Res

View full text Add to dashboard Cite

Primary cutaneous lymphomas (PCLs) are the second most common group of extranodal non-Hodgkin lymphomas (NHL) with an estimated annual incidence of 1/100.000. Interferons (IFNs) are used in mono or combination therapy for cutaneous lymphomas especially for cutaneous T-cell lymphomas (CTCL) for years. IFN-α is the most widely-used type for cutaneous lymphomas. IFN-α has been shown to be a highly active agent in CTCL with response rates ranging from 40% to 80%. In this review, the current information about PCLs and IFNs treatment is summarized.

show abstract

Adult T-cell leukemia/lymphoma

Abstract: Adult t-cell leukemiA/lymphomA rev assoC med bras 2016; 62 (7):691-700 691

Cited by 20 publications

References 69 publications

Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study

Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study

Vitamin D and HTLV Infection: A Systematic Review

Primary Cutaneous Lymphomas and Interferon Treatment

Contact Info

Product

Resources

About